Diligence memo · auto-generated · as of July 3, 2026
Intrommune Therapeutics, Inc.
Intrommune Therapeutics, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Intrommune Therapeutics, Inc. operates in Biotechnology, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Intrommune Therapeutics, Inc. has raised $25M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2021-06-23.
Most recent recorded round closed around 2023-12-06.
Valuation (modeled)modeled
Provath models Intrommune Therapeutics, Inc. at approximately $1.9M (range $420K–$3.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.01× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 15.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 72% of Biotechnology peers (4293 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.